%0 Generic
%A Baniandres-Rodriguez, Ofelia
%A Vilar-Alejo, Jaime
%A Rivera, Raquel
%A Carrascosa, Jose Manuel
%A Dauden, Esteban
%A Herrera-Acosta, Enrique
%A Sahuquillo-Torralba, Antonio
%A Gomez-Garcia, Fran J
%A Nieto-Benito, Lula Maria
%A de la Cueva, Pablo
%A Lopez-Estebaranz, Jose Luis
%A Belinchon, Isabel
%A Ferran-Farres, Marta
%A Alsina, Merce
%A Rodriguez-Fernandez-Freire, Lourdes 
%A Carretero, Gregorio
%A Garcia-Donoso, Carmen
%A Ballesca, Ferran
%A Llamas-Velasco, Mar
%A Herrera-Ceballos, Enrique
%A Botella-Estrada, Rafael
%A Ruiz-Genao, Diana Patricia
%A Riera-Monroig, Josep
%A Descalzo-Gallego, Miguel Angel
%A Garcia-Doval, Ignacio
%T Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.
%D 2020
%U http://hdl.handle.net/10668/16501
%X To the Editor: The use of systemic treatments in psoriatic patients during the pandemic has been the subject of extensive debate. In March 2020, weperformed a specific study within the cohort of Biobadaderm Registry, a previously described national, multicenter, prospective cohort. Our primary objective was to analyze the incidence of COVID-19 infections and severeoutcomes in a cohort of psoriatic patients treated with systemic therapies and to compare it with that of the general population. We reviewed all Biobadaderm patient records and contacted the patients when needed. We collected information about current comorbidities related to COVID-19 and COVID-19 outcomes in all active patients of the registry. We used the latest data updated on July 6, 2020.
%K Psoriasis
%K Registries
%K Severity of Illness Index
%K Spain
%~